Figure 2.
Ki67-ZD55-IL-24 inhibited the growth of melanoma cells but did not have overlapping toxicity in normal cells. (A) The expression of Ki67 in melanoma cells and normal NHLF cells was assessed by immunocytochemical analysis. Representative pictures for different cell groups (original magnification, × 400). (B) Cytolytic activities of Ki67-ZD55-IL-24 in A375, M14, and NHLF cells. Cells were plated at a density of 105 cells per 6-cm dish and treated with ZD55-EGFP, Ki67-ZD55, ZD55-IL-24, or Ki67-ZD55-IL-24, respectively, at the indicated dosage. They were stained with crystal violet at day 7. The presence of staining indicates the presence of live cells. (C) Melanoma A375 and M14 cells and normal NHLF cells were respectively infected with ZD55-EGFP, Ki67-ZD55, ZD55-IL-24, or Ki67-ZD55-IL-24 at an MOI of 10. On days 1, 2, 3, and 4 post infection, the cells were subjected to the MTT assay. A375 and M14 cells and normal NHLF cells were treated with ZD55-EGFP, Ki67-ZD55, ZD55-IL-24, or Ki67-ZD55-IL-24, respectively, at the indicated dosages. The cells were subjected to the MTT assay on the fourth day after treatment. The results are expressed as mean±s.d. (error bars) as the percentage of untreated control cells (n=6).